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A series of metal-chelating lipid conjugates has been designed and synthesized. Each member of the series
bears a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) macrocycle attached to the lipid
head group, using short n-ethylene glycol (n-EG) spacers of varying length. Liposomes incorporating these
lipids, chelated toGd3þ, 64Cu2þ, or 111In3þ, and also incorporatingﬂuorescent lipids, have beenprepared, and
their application in optical, magnetic resonance (MR) and single-photon emission tomography (SPECT)
imaging of cellular uptake and distribution investigated in vitro and in vivo. We have shown that these
multimodal liposomes canbeused as functionalMRcontrast agents aswell as radionuclide tracers for SPECT,
and that they can be optimized for each application. When shielded liposomes were formulated incorpo-
rating 50%of a lipidwith a shortn-EG spacer, to give nanoparticleswith a shallowbut even coverage of n-EG,
they showedgood cellular internalization in a range of tumour cells, compared to the limited cellular uptake
of conventional shielded liposomes formulatedwith7%1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[carboxy(polyethyleneglycol)2000] (DSPE-PEG2000).Moreover, bymatching thedepthofn-EGcoverage to
the length of the n-EG spacers of the DOTA lipids, we have shown that similar distributions and blood half
lives toDSPE-PEG2000-stabilized liposomes can be achieved. The ability to tune the imaging properties and
distribution of these liposomes allows for the future development of a ﬂexible tri-modal imaging agent.
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The use of liposomes for the targeted delivery of therapeutic
small molecules, DNA, or siRNA to tumours has generated a great
deal of interest in the cancer research community [1]. Liposomes
are versatile nanoparticles with low toxicity that can be formulated
from a range of natural and biologically inspired synthetic lipids.
They have been extensively used in the clinic as drug carriers to
reduce the toxicity of potent drugs, such as doxorubicin, to non-
cancerous cells and tissues. Hydrophilic drugs can be trapped in
the central aqueous core of the liposomes, and lipophilic drugs can
be solubilised within the lipid bilayer [1]: in either case, the drug
cannot readily pass through the lipid bilayer and is trapped within
the liposome until the nanoparticle reaches the tumour. For
successful in vivo applications, it has been established that the outer
bilayer of the liposome should ideally be coated with a neutral
polyethylene glycol (PEG) polymer to minimize colloidal instability,
N. Mitchell et al. / Biomaterials 34 (2013) 1179e11921180reducing bioadhesion and limiting immunological responses [2].
Most importantly, the PEG coating reduces uptake of the liposome
within the reticuloendothelial system (RES) and therefore slows
the rate of removal of the liposomes from the blood [2]. This
effectively increases the biological half-life of the liposome; in
clinical studies conventional liposomes have been shown to have
a half-life of 20 min in body ﬂuids, whereas PEG-liposomes can
have a half-life of up to 5 days [3], allowing for greater payloads of
drug to be delivered to the tumour before clearance. Liposomal
formulations of anticancer drugs have now been approved for
clinical use: DOXIL (PEGylated liposomal doxorubicin) is used to
treat AIDS-related Kaposi’s sarcoma and multiple myeloma [4] and
is in clinical trials for the treatment of breast cancer [1].
The PEG coating of liposomes is also highly advantageous in
terms of passive targeting to tumours. Tumour vasculature is
characterized by a chaotic network of thin-walled, leaky vessels [5]
and therefore liposomes are able to cross into the interstitial spaces
in viable tumour areas with limited wash out, a process referred to
as the enhanced permeability and retention (EPR) effect [6]. Small
PEG-liposomes, 100e200 nm in diameter, are the right size to
permeate through the tumour vasculature, and have been shown to
accumulate in tumour tissue. However, liposomal particles with
high percentages of long chain PEG, such as PEG2000, at the ratios
needed for in vivo applications, have shown limited uptake in cells
in vitro [7]. This problem is particularly acute when liposomes areFig. 1. Neutral, cationic and PEG-lipids used in this study. General structure of DOTA-lipids ch
liposomes formulated.used to deliver DNA or siRNA, as the resulting PEG-coated lip-
oplexes are also frequently too stable to disassemble once inter-
nalized in the endosome [8]. Targeting moieties, such as ligands for
receptor mediated uptake, have therefore been used to enhance the
uptake of PEG-liposomes [7], although this approach is not always
effective [9].
We have previously developed ternary lipid-peptide-DNA lip-
opolyplex vectors that have been formulated with cationic lipids
bearing short n-ethylene glycol (n-EG) units (e.g. n ¼ 4: DODEG4
(Fig. 2), or n ¼ 6), based on the structure of (N-[1-(2,3-dioleyloxy)
propyl])-N,N,N-trimethylammonium chloride (DOTMA) [10,11].
These lipopolyplexes also incorporate multifunctional peptides
comprising both a cationic sequence for the complexation of plasmid
DNA and an integrin-binding sequence to target the nanoparticles to
cells of interest [11]. We have co-formulated the n-EG cationic lipids
with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in
a 1:1 (w:w) ratio of cationic lipid:DOPE, to give a vector which we
hypothesise is shielded by an even coverage of short n-ethylene
glycol units. These shielded lipopolyplexes were demonstrated to be
compact, stable under physiologically relevant conditions, and
maintain tumour-speciﬁc targeting and transfection properties
invitro [11] and invivo [12]. In contrast, inpreviously reported studies
of PEG-liposomes [2], the maximum possible loading of shielding
lipids suchasDSPE-PEG2000 is about10%ofPEG-lipid, resulting inan
incomplete surface coverage.elated to paramagnetic or radioactive ions, and schematic showing the multifunctional
Fig. 2. A) Brightﬁeld and corresponding Fl-DHPE ﬂuorescence images for MDA-MB-231 cells incubated with DODEG4 liposomes A-C formulated with DEG1SL, DEG3SL and DEG6SL
respectively, compared to the control PEG2000 liposome D formulated with DEG3SL (X100 magniﬁcation). B) Changes in T1 relative to the degree of uptake of Gd-DEG3SL (liposome
B) for three different cell types HeLa, MDA-MB-231, and OVCAR-3 compared to control cells. C) Dose dependent changes in T1 for MDA-MB-231 cells incubated with Gd-DEG3SL
(liposome B).
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therapeutic agents with the capacity for in vivo imaging are attrac-
tive as they enable simultaneous monitoring and treatment of
diseases. In recent years there has been considerable interest in the
development of such theranostic nanoparticles [13], which allow
the distribution, selectivity, efﬁcacy and uptake of the therapeutic
agent in target tissues to be determined. In previous research,
liposomal delivery of therapeutic agents has been combined with
imaging techniques such asmagnetic resonance imaging (MRI) [13e
20], positron or single-photon emission tomography (PET/SPECT)
[21e23] and ﬂuorescence [13e17]. These imaging methods are
currently at the forefront of medical diagnostics and widely used in
the preclinical and clinical settings for assessment of treatment
efﬁcacy. MRI is a non-invasive and widely used imaging modality
that produces excellent soft tissue contrast and spatial resolution.
However, MRI suffers from poor sensitivity, and therefore the target
to be imaged either has to be expressed at a high level, or
approaches to increase the contrast payload are needed [14,24]. In
contrast, nuclear imaging with PET and SPECT methods provides
exquisite sensitivity but has limited spatial and temporal resolution
[25]. Therefore, there is a need to combine these imaging modalities
in order to elucidate the biological behaviour of liposomes from the
cellular level to the macroscopic scale. A drug delivery system that
incorporates reporter groups for these imaging modalities would be
highly desirable, and a multimodal approach that encompasses all
three would be ideal, as it would allow the limitations of each
imaging modality to be overcome [26].One of the most straightforward approaches for the incorpora-
tion of both the MRI contrast agent Gd3þ, and appropriate radio-
nucleides for PET/SPECT nuclear imaging, into liposomes, is to use
a chelating ligand, suitably modiﬁed for attachment to an organic
scaffold or small molecule [27,28]. An ideal chelator for these
purposes is the macrocycle 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), which has been used extensively
for the chelation of a range of metal ions that can provide MRI
contrast or PET/SPECT imaging. Due to its cyclic nature, the disso-
ciation of the metal ion from the complex is very slow, especially
when compared to linear chelators such as diethylenetriamine
pentacetic acid (DTPA), signiﬁcantly lowering the toxicity of DOTA-
chelated contrast agents [29]. Gd.DOTA (Dotarem) is clinically
approved for use in MRI and has been used previously for the
attachment of Gd-chelates to the head group of various lipids [27].
The nature of the groups attached to the DOTA, ﬂexibility of the
linker between the liposome and the chelate, and the size of the
resulting complex, can all be used to tune the sensitivity of the
resulting contrast agent [27,28]. Similarly, liposomes labelled with
awide range of radionuclides have been reported for PETand SPECT
nuclear imaging, and for targeted radiotherapy [30], although the
majority of these radioactive liposome formulations rely on the
encapsulation of radionuclide chelates rather than the inclusion of
chelating lipids.
The aim of this study was to develop a multifunctional, multi-
modal shielded liposomal formulation, incorporating: lipids that
have short n-EG units to shield the liposomes in vivo; DOTA-lipids
N. Mitchell et al. / Biomaterials 34 (2013) 1179e11921182with short n-EG units which can chelate paramagnetic ions and/or
radionuclides; a ﬂuorophore-labelled lipid to allow for optical
imaging; and the helper lipid DOPE (Fig. 1). We have designed and
synthesized three lipids with DOTA attached at the head group, and
with different length n-EG spacer units between DOTA and the lipid
acyl chains. Chelation of paramagnetic (Gd3þ) ions to the conju-
gated DOTA, will allow these liposomes to be used for the devel-
opment of imaging tracers for MRI. Similarly, chelation of
radioactive ions to the DOTA, post-formulation, will lead to tracers
for PET or SPECT. 64Cu was selected for these studies. This is
increasingly seen as the radionuclide of choice for in vivo PET
studies as it has a relatively long half-life (12.7 h); gives high-
quality PET images, and can also be used in radionuclide therapy
[31]. Similarly, 111In has a long half life (2.8 days) and is in clinical
use for several applications [32]. Both radionuclides are effectively
chelated by DOTA with good in vivo kinetic stability.
It was particularly important when developing these systems to
compare the biodistribution characteristics of shielded liposomes
formulated with varying amounts of lipids bearing short n-EG
units, to that of liposomes formulated with PEG2000-bearing lipids
to enable future targeting applications for drug delivery and diag-
nostic imaging.
2. Materials and methods
2.1. Materials
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carboxy(polyethyleneglycol)2000], ammonium
salt (DSPE-PEG2000) and N-(ﬂuorescein-5-thiocarbamoyl)-1,2-dihexa-decanoyl-sn-
glycero-3-phosphoethanolamine, triethylammonium salt (FL-DHPE) were
purchased from Avanti Polar Lipids Inc. (Alabaster, AL). [111In]-InCl3 was purchased
from Covidien Commercial Ltd, Hants UK. [64Cu]-CuCl2 was produced by proton
bombardment of enriched Ni-64 metal and puriﬁed as previously described using
Fraction 9 [33]. All other reagents were purchased from SigmaeAldrich Co. Ltd.
unless otherwise stated, and used without further puriﬁcation. All reagents were of
commercial quality and used as received and all solvents anhydrous. Thin Layer
Chromatography (TLC) was performed on aluminium backed SigmaeAldrich TLC
plates with F254 ﬂuorescent indicator. Visualisation was done by quenching of UV
ﬂuorescence or by staining the plates with potassium permanganate solution
[KMnO4 (1.25 g), Na2CO3 (6.25 g), water (250 mL)]. ITLC-SA plates were from Varian/
Agilent. Normal phase ﬂash chromatography was carried out using silica gel (43e
60 mm) supplied by Merck. LC/MS was performed on a Waters Acquity uPLC SQD
using HPLC gradewater and acetonitrile (both with 0.1% formic acid) as the solvents.
MALDI MS was performed on a Waters MALDI MicroMX machine using a-cyano-4-
hydroxycinnamic acid (CHCA) or sinapinic acid (SA) as the matrix (1 mg/mL in
methanol). NMR (1H and 13C) was performed on either 500 or 600 MHz AMX Bruker
Spectrometers (as stated). The chemical shifts (d) were given in units of ppm relative
to tetramethylsilane (TMS), where d (TMS) ¼ 0 ppm. Coupling constants (J) were
measured in Hertz (Hz), multiplicities for 1H coupling are shown as s (singlet),
d (doublet), t (triplet), m (multiplet), or a combination of the above. Deuterated
chloroform (CDCl3), dimethylsulfoxide (d6-DMSO) and methanol (CD3OD) were
used as solvents (as stated) for all NMR analysis. Dynamic light scattering and zeta
potential measurements were performed using a Malvern Zetasizer Nano-ZS
(Malvern, UK). MRI experiments were conducted on a Agilent 9.4 T scanner (Agi-
lient Inc. Palo Alto, CA, USA) using a 39 mm coil (RAPID Biomed, Rimpar, Germany).
SPECT/CT experiments were carried out using a NanoSPECT/CT scanner (Mediso,
Hungary). All procedures on animals were conducted in accordance with UK and
Home Ofﬁce regulations and the Guidance for the Operation of Animals (Scientiﬁc
Procedures) Act (1986).
2.2. Chemical synthesis
Ethylene diamine (1) and 3,6-dioxaoctane-1,8-diamine (2) were converted into
the mono-Boc compounds tert-butyl 2-aminoethylcarbamate (4) and tert-butyl 8-
amino-3,6-dioxaoctylcarbamate (5) as previously described [34,35]. 3,6,9,12,15-
Pentaoxaheptadecane-1,17-diamine (3) was prepared from hexaethylene glycol as
previously reported [36,37]. 4-(2-(Tert-butoxycarbonylamino)ethylamino)-4-
oxobutanoic acid (7) [38], 3-bis[(Z)-octadec-9-enyloxy]propan-1-amine (10) [39],
4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic
acid 14 [40], N-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)-N,N-dimethyl-2,3-
bis((Z)-octadec-9-enyloxy)propan-1-aminium (DODEG4) [10] and N-[1-(2,3-
dioleyloxy)propyl])-N,N,N-trimethylammonium chloride (DOTMA) [39,41] were all
prepared as previously described.tert-Butyl 17-amino-3,6,9,12,15-pentaoxaheptadecylcarbamate (6) The reac-
tion was carried out under anhydrous conditions. To 3,6,9,12,15-penta
oxaheptadecane-1,17-diamine 3 (1.20 g, 4.28 mmol) in dichloromethane (100 mL)
at 0 C was added di-tert-butyl dicarbonate (0.470 g, 2.15 mmol). The solution was
stirred at room temperature for 18 h, then the solvent removed in vacuo and the
crude material puriﬁed via silica column chromatography (gradient 10e50% MeOH
in CH2Cl2) to give 6 (comparable by NMR to the previous report [42]) as a colourless
oil (0.594 g, 73%). Rf 0.40 (20% MeOH in CH2Cl2); 1H NMR (500MHz; CDCl3) d 1.42 (s,
9H), 2.72 (br s, 3H), 2.89 (t, J ¼ 4.9 Hz, 2H), 3.30 (m, 2H), 3.53e3.65 (m, 20H); 13C
NMR (125 MHz; CDCl3) d 28.5, 41.7, 53.5, 70.2e70.6 (signals superimposed), 72.3,
79.2, 156.2; m/z (ESþ) 381 (MHþ, 100%).
2,2-Dimethyl-4,15-dioxo-3,8,11-trioxa-5,14-diazaoctadecan-18-oic acid, trie-
thylamine salt (8.triethylamine salt). The reaction was carried out under anhy-
drous conditions. To tert-butyl 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate (5)
(1.00 g, 4.03 mmol) in dichloromethane (50 mL) was added triethylamine (1.12 mL,
8.04 mmol) and succinic anhydride (0.443 g, 4.43 mmol). The reactionwas stirred at
room temperature for 3 h, then a further 0.4 equiv of succinic anhydride was added
and the reaction stirred for 18 h. The solvent was removed under reduced pressure
to yield a dark purple crude oil, which was puriﬁed via ﬂash silica chromatography
(gradient 5% MeOH and 1% triethylamine in CH2Cl2, to 10% then 20% MeOH in
CH2Cl2) to give the triethylamine salt of 8 (comparable by NMR to the free acid [43])
(1.63 g, 90%) as a colourless oil. Rf 0.52 (10% MeOH in CH2Cl2); 1H NMR (500 MHz;
CDCl3) d 1.14 (t, J¼ 7.3 Hz, 9H),1.35 (s, 9H), 2.38e2.46 (m, 4H), 2.89 (q, J¼ 7.3 Hz, 6H),
3.22 (m, 2H), 3.33 (m, 2H), 3.46 (m, 4H), 3.52 (m, 4H), 5.26 (br s, 1H), 7.10 (br s, 1H);
13C NMR (125 MHz; CDCl3) d 8.6, 28.2, 32.6, 32.8, 38.9, 40.2, 44.8, 69.8e70.0 (signals
superimposed), 78.9, 156.0, 173.5, 178.4; m/z [HRMS ESþ] found, 371.1801.
C15H28N2O7Na requires 371.1794.
1-Amino-Boc-19-oxo-3,6,9,12,15-pentaoxa-18-azadocosan-22-oic acid (9).
The reaction was carried out under anhydrous conditions. To compound 6 (572 mg,
1.50 mmol) in dichloromethane (50 mL) was added triethylamine (420 mL,
3.01 mmol) and succinic anhydride (301 mg, 3.01 mmol). The solutionwas stirred at
room temperature for 5 h, then the solvent removed under reduced pressure. The
crude material was puriﬁed via silica column chromatography (gradient 5e20%
MeOH in CH2Cl2) to give 9 (415 mg, 58%) as an oil. Rf 0.33 (10% MeOH in CH2Cl2);
nmax(CHCl3)/cm1 3332, 2873, 1784, 1708; 1H NMR (500 MHz; CDCl3) d 1.44 (s, 9H),
2.51 (t, J ¼ 6.2 Hz, 2H), 2.60 (m, 2H), 3.30 (m, 2H), 3.43 (m, 2H), 3.53e3.67 (m, 20H),
5.24 (br s, 1H), 7.05 (br s, 1H); 13C NMR (125MHz; CDCl3) d 28.6, 31.7, 31.8, 39.4, 40.4,
69.8e70.6 (signals superimposed), 79.4, 156.3, 173.6, 176.8; m/z [HRMS ESþ] found,
503.2583. C21H40N2O10Na requires 503.2581.
N1-(2-aminoethyl)-N4-(2,3-bis((Z)-octadec-9-enyloxy)propyl)succinamide
(11). To the acid 7 (555 mg, 2.13 mmol) was added HBTU (971 mg, 2.56 mmol) in
anhydrous dichloromethane (30 mL), diisopropylethylamine (DIPEA) (744 mL,
4.27 mmol), and amine 10 (1.26 g, 2.13 mmol). The solution was stirred at room
temperature for 4 h, then the solvent removed under reduced pressure and the crude
product puriﬁed via silica column chromatography (5%MeOH in CH2Cl2) to yield the
Boc-protected intermediate, tert-butyl 2-(4-(2,3-bis((Z)-octadec-9-enyloxy)propy-
lamino)-4-oxobutanamido)ethyl carbamate (998 mg, 79%) as an light orange oil. Rf
0.57 (15%MeOH inCH2Cl2); 1HNMR(600MHz;CDCl3) d0.87 (t, J¼7.0Hz, 6H),1.26 (m,
44H),1.43 (s, 9H),1.54 (m, 4H),1.94e2.02 (8H,m, CH2CH¼CHCH2), 2.47e2.53 (m, 4H),
3.24e3.35 (m, 4H), 3.37e3.57 (m, 9H), 5.04 (br t,1H), 5.33 (m, 4H), 6.21 (br t,1H), 6.52
(br t, 1H); 13C NMR (150 MHz; CDCl3) d 14.3, 22.8, 26.2, 27.3, 28.8, 29.2e29.9 (signals
superimposed), 30.2, 31.8, 32.0, 32.7, 38.7, 40.3, 40.6, 70.4, 71.5, 71.9, 76.6, 79.7,129.9,
130.5, 156.8, 172.6, 174.5; m/z (ESþ) 835 (MHþ, 90%). The Boc group was then
deprotected with 1:1 CH2Cl2:TFA (10 mL) for 3 h at room temperature. The solvents
were removed in vacuo and the product dried under vacuo to give 11 (quantitative
yield) as a light orangeoil. Rf 0.39 (15%MeOH inCH2Cl2); nmax (neat)/cm13289, 2924,
2853,1647; 1HNMR (500MHz; CDCl3) d 0.87 (t, J¼ 7.0 Hz, 6H),1.26 (m, 44H),1.55 (m,
4H), 2.00 (m, 8H), 2.50 (m, 2H), 2.56 (m, 2H), 3.26 (m,1H), 3.37e3.56 (m,12H), 5.34 (m,
4H), 6.18 (br t, 1H), 6.90 (br t, 1H), 8.26 (br t, 2H); 13C NMR (150 MHz; CDCl3) d 14.2,
22.8, 26.2, 27.3, 29.4e29.9 (signals superimposed), 30.1, 31.1, 31.6, 31.7, 32.0, 32.7, 39.0,
40.8, 41.1, 70.3, 71.5, 72.0, 76.4, 129.9, 130.1, 172.3, 174.4; m/z [HRMS ESþ] found,
734.6710. C45H88N3O4 requires 734.6775.
N1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-N4-(2,3-bis((Z)-octadec-9-enyloxy)
propyl) succinamide (12) The reaction was carried out under anhydrous conditions.
To the triethylamine salt of acid 8 (438 mg, 0.975 mmol) in dichloromethane (50 mL)
was added HBTU (716 mg, 1.89 mmol) DIPEA (438 mL, 2.52 mmol) and amine 10
(496 mg, 0.840 mmol). The solution was stirred at room temperature for 18 h. The
crude oil was dry loaded onto a silica column and puriﬁed via ﬂash chromatography
(0,1%, 2%, then 5%MeOH in CH2Cl2) to yield the Boc-protected intermediate tert-butyl
(Z)-16-((Z)-octadec-9-enyloxy)-10,13-dioxo-3,6,18-trioxa-9,14-diazahexatriacont-27-
enyl carbamate (696 mg, 77%) as a colourless oil. Rf 0.54 (10% MeOH in CH2Cl2); 1H
NMR (600 MHz; CDCl3) d 0.87 (t, J ¼ 6.9 Hz, 6H), 1.26e1.32 (m, 44H), 1.44 (s, 9H), 1.55
(m, 4H), 1.94e2.02 (m, 8H), 2.51 (m, 4H), 3.27e3.74 (m, 21H), 5.14 (br s, 1H), 5.30e
5.36 (m, 4H), 6.15 (br s, 1H), 6.45 (br s, 1H); 13C NMR (150 MHz; CDCl3) d 14.3, 22.8,
26.2, 27.3, 28.5, 29.3e29.9 (signals superimposed), 30.2, 32.0, 32.7, 39.4, 40.4, 41.0,
69.9, 70.3, 70.4 (signals superimposed), 71.5, 71.9, 79.4, 129.9, 130.4, 156.2, 172.1;m/z
(ESþ) 823 ([MHþ-Boc], 100%). The Boc group was then deprotected with 1:1
CH2Cl2:TFA (5 mL) for 3 h at room temperature. The solvents were removed in vacuo
and the product puriﬁed via silica column chromatography (gradient 5e15%MeOH in
N. Mitchell et al. / Biomaterials 34 (2013) 1179e1192 1183CH2Cl2) to give 12 in quantitative yield as a colourless oil. Rf 0.20 (10% MeOH in
CH2Cl2); nmax(CHCl3)/cm1 3292, 2926, 2854, 1669; 1H NMR (600 MHz; CDCl3) d 0.86
(t, J ¼ 6.9 Hz, 6H), 1.24e1.28 (m, 44H), 1.54 (m, 4H), 1.94e2.0 (m, 8H), 2.52 (m, 4H),
3.14 (m, 2H), 3.23 (m, 1H), 3.36e3.58 (m, 10H), 3.63 (m, 4H), 3.66 (m, 2H), 3.75 (m,
2H), 5.30e5.39 (m, 4H), 6.56 (br s,1H), 7.83 (br s, 1H); 13C NMR (150 MHz; CDCl3)
d 14.2, 22.8, 25.1, 26.2, 27.4, 29.3e29.9 (signals superimposed), 30.1, 30.6, 30.9, 32.0,
32.7, 33.8, 39.5, 39.8, 41.1, 66.9, 69.8, 69.9, 70.4, 71.3, 71.9, 76.6, 129.9, 130.0,173.5;m/z
[HRMS ESþ] found, 822.7242. C47H97N3O6Na requires 822.7275.
N1-(17-amino-3,6,9,12,15-pentaoxaheptadecyl)-N4-(2,3-bis((Z)-octadec-9-
enyloxy) propyl) succinamide (13). The reaction was carried out under anhydrous
conditions. To the acid 9 (415 mg, 0.864 mmol) in dichloromethane (30 mL) was
added HBTU (394mg,1.04mmol), DIPEA (301mL,1.73mmol) and amine 10 (512mg,
0.865 mmol) in dichloromethane (5 mL). The solution was stirred at room
temperature for 18 h, then the solvent removed under reduced pressure and the
crude product puriﬁed via silica column chromatography (5% MeOH in CH2Cl2) to
yield the Boc-protected intermediate, tert-butyl (Z)-25-((Z)-octadec-9-enyloxy)-
19,22-dioxo-3,6,9,12,15,27-hexaoxa-18,23-diazapenta-tetra-cont-36-enylcarbamate
(768 mg, 93%) as a light yellow oil. Rf 0.71 (10%MeOH in CH2Cl2); 1H NMR (600MHz;
CDCl3) d 0.86 (t, J ¼ 7.0 Hz, 6H), 1.23e1.31 (m, 44H), 1.45 (s, 9H), 1.53 (m, 4H), 1.94e
2.01 (m, 8H), 2.51 (m, 4H), 3.17e3.72 (m, 35H), 5.29 (br s, 1H), 5.32e5.36 (m, 4H),
6.33 (br s, 1H), 6.73 (br s, 1H); 13C NMR (150MHz; CDCl3) d 14.3, 22.8, 26.2, 27.3, 28.5,
29.4e29.9 (signals superimposed), 30.2, 31.7, 31.8, 32.0, 32.7, 39.3, 40.3, 41.0, 43.7,
70.1e70.4 (signals superimposed), 71.5, 71.9, 79.4, 129.9, 130.4, 156.6, 172.4, 172.9;m/
z (ESþ) 1055 (MHþ, 40%). The Boc group was then deprotected with 1:1 CH2Cl2:TFA
(10 mL) for 3 h at room temperature. The solvents were removed in vacuo and the
product puriﬁed via silica column chromatography (gradient 5e15% MeOH in
CH2Cl2) to give 13 in quantitative yield as a light yellow oil. Rf 0.44 (10% MeOH in
CH2Cl2); nmax(neat)/cm1 2925, 2855, 1778; 1H NMR (600 MHz; CDCl3) d 0.86 (t,
J ¼ 7.0 Hz, 6H), 1.23e1.30 (m, 44H), 1.53 (m, 4H), 1.94e2.00 (m, 8H), 2.48 (m, 4H),
2.52 (m, 4H), 3.24 (m, 1H), 3.39e3.63 (m, 32H), 5.32e5.36 (m, 4H), 6.39 (br s, 1H),
7.01 (br s, 1H), 8.39 (br s, 2H); 13C NMR (150 MHz; CDCl3) d 14.2, 22.8, 26.2, 27.3,
29.3e29.9 (signals superimposed), 30.1, 31.5, 31.8, 32.0, 32.7, 37.6, 39.4, 39.9, 40.9,
69.0, 69.9, 70.1, 70.4e70.6 (signals superimposed), 71.5, 71.9, 76.8,129.9, 130.0,172.3,
172.4; m/z [HRMS ESþ] found, 954.8071. C55H108N3O9 requires 954.8086.
2,2,2-(10-((Z)-13-((Z)-octadec-9-enyloxy)-2,7,10-trioxo-15-oxa-3,6,11-
triazatritriacont-24-enyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triethanoic
acid (15). The reaction was carried out under anhydrous conditions. To the DOTA
derivative14 (15.6mg,27.3mmol),HBTU(15.5mg,42mmol)andDIPEA(10mL, 57.5mmol)
in dichloromethane (5 mL) was added amine 11 (20 mg, 27.3 mmol). The reaction was
stirred at room temperature for 4 h, after this time the solvent was removed under
reducedpressure and the crudeproduct puriﬁedvia silica column chromatography (0e
2%MeOH in CH2Cl2) to give the protected intermediate, 2,2,2-(10-((Z)-13-((Z)-octadec-
9-enyloxy)-2,7,10-trioxo-15-oxa-3,6,11-triazatritriacont-24-enyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triethanoic acid tri-tert-butyl ester (10 mg, 28%) as
a colourless oil. 1H NMR (600MHz; CDCl3) d 0.87 (t, J¼ 7.0 Hz, 6H),1.26e1.30 (m, 44H),
1.45 (m, 27H),1.55 (m, 4H), 2.01 (m, 8H), 2.51 (m, 4H), 3.28e3.56 (m, 21H), 5.36 (m, 4H),
6.35 (br t, J¼5.5Hz,1H),6.48 (br t, J¼5.6Hz,1H), 6.82 (br t, J¼5.4Hz,1H),notee signals
masked under line broadening 2e3 ppm; 13C NMR (150MHz; CDCl3) d 14.3, 22.8, 26.2,
27.4, 28.0 (signals superimposed), 29.3e29.9 (signals superimposed), 30.2, 32.0, 32.2,
32.8, 39.3, 39.6, 40.8, 48.4 (br), 52.7 (br), 55.8 (signals superimposed), 70.4, 71.5, 71.8,
82.1, 130.0,130.5, 172.1,172.5, 173.3;m/z (ESþ) 1288 (MHþ, 30%), 645 ([MH2]2þ/2, 90%).
The tri-tert-butyl ester was then deprotected in 1:1 CH2Cl2:TFA (5 mL) for 3 h at room
temperature. The solventswere removed invacuo and the product driedunder vacuo to
give15 (quantitativeyield)asacolourlessoil. Rf0.63 (15%MeOHinCH2Cl2); nmax(CHCl3)/
cm1 2924, 2854,1652; 1H NMR (600MHz; CD3OD) d 0.90 (t, J¼ 7.0 Hz, 6H), 1.29e1.38
(m, 44H),1.51 (m, 4H),1.98e2.05 (m, 8H), 2.51 (m, 4H), 3.19e3.73 (m, 21H), 5.35 (m, 4H),
note e signals masked by line broadening 3.2e3.7 ppm; 13C NMR (150 MHz; CD3OD)
d14.5, 23.8, 27.3, 28.2, 28.5, 30.2e30.9 (signals superimposed), 31.2, 33.1, 33.7, 34.7, 39.6,
40.2, 41.7, 43.8, 55.8, 71.3, 72.4, 72.6, 78.6, 130.8, 131.5, 161.3, 174.8, 175.2; m/z [HRMS
ESþ] found, 1120.8534. C61H114N7O11 requires 1120.8576.
2,2,2-10-((Z)-19-((Z)-octadec-9-enyloxy)-2,13,16-trioxo-6,9,21-trioxa-3,12,17-
triaza nona triacont-30-enyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) trie-
thanoic acid (16). The reaction was carried out under anhydrous conditions. To the
DOTA derivative 14 (60 mg, 0.105 mmol) in dichloromethane (10 mL), was added
HBTU (40 mg, 0.105 mmol) and DIPEA (37 mL, 0.212 mmol) and amine 12 (86 mg,
0.105 mmol). The reaction was stirred at room temperature for 4 h, the solvent
removed under reduced pressure and the crude product puriﬁed via silica column
chromatography (6% MeOH in CH2Cl2) to afford the protected intermediate, 2,2,2-10-
((Z)-19-((Z)-octadec-9-enyloxy)-2,13,16-trioxo-6,9,21-trioxa-3,12,17-
triazanonatriacont-30-enyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triethanoic
acid tri-tert-butyl ester (93 mg, 65%) as a colourless oil. 1H NMR (500 MHz; CDCl3)
d 0.87 (t, J ¼ 7.2 Hz, 6H), 1.25 (m, 44H), 1.45 (m, 27H), 1.55 (m, 4H), 1.95e2.02 (m, 8H),
2.51 (m, 4H), 3.26e3.30 (m, 2H), 3.37e3.65 (m, 19H), 5.33e5.38 (m, 4H), 6.38 (br t,
J ¼ 5.6 Hz, 1H), 6.48 (br t, J ¼ 5.9 Hz, 1H), 6.74 (br t, J ¼ 5.6 Hz, 1H), note e signals
masked under line broadening 2.0e3.2 ppm; 13C NMR (125 MHz; CDCl3) d 14.3, 22.8,
26.2, 27.3, 28.0, 28.1, 29.3e29.9 (signals superimposed), 30.2, 31.8, 32.0, 32.8, 38.7,
39.3, 40.9, 68.9, 69.6, 69.8, 70.3, 70.4, 71.6, 71.9, 72.0, 82.0, 130.0, 130.5, 171.9, 172.4,
172.5, 172.6; m/z (ESþ) 1377 (MHþ, 100%). The tri-tert-butyl ester was then depro-
tected in 1:1 CH2Cl2:TFA (5 mL) for 3 h at room temperature. The solvents wereremoved in vacuo and the product dried under vacuo to give 16 (quantitative yield) as
a colourless oil. Rf 0.81 (10% MeOH in CH2Cl2); nmax(CHCl3)/cm1 2926, 2854, 1724,
1663; 1H NMR (600 MHz, CD3OD) d 0.90 (t, J ¼ 7.0 Hz, 6H), 1.22 (m, 44H, m), 1.56 (m,
4H), 1.98e2.05 (m, 8H), 2.49 (s, 4H), 3.19e3.65 (m, 21H), 5.34e5.39 (m, 4H), note e
some signalsmasked under line broadening 3.2e3.7 ppm; 13C NMR (125MHz, CDCl3)
d 14.5, 23.8, 26.1, 27.3, 28.2, 30.2e30.9 (signals superimposed), 31.2, 32.1, 32.2, 33.0,
33.1, 33.7, 34.7, 38.9, 40.3, 41.6, 69.8, 70.4, 70.5, 71.2, 71.3, 72.4, 72.6, 78.6, 81.3, 130.8,
131.6, 174.7; m/z [HRMS ESþ] found, 1208.8995. C65H122N7O13 requires 1208.9101.
2,2,2-10-((Z)-28-octadec-9-enyloxy)-2,22,25-trioxo-6,9,12,15,18,30-hexaoxa-
3,21,26-triaza octa tetracont-39-enyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)
triethanoic acid (17). The reaction was carried out under anhydrous conditions. To
the DOTA derivative 14 (140mg, 0.244mmol) in dichloromethane (10mL)was added
HBTU (111 mg, 0.293 mmol), DIPEA (213 mL, 1.22 mmol) and amine 13 (280 mg,
0.294 mmol). The reaction was stirred at room temperature for 3 h, the solvent
removed under reduced pressure and the crude product puriﬁed via silica column
chromatography (gradient 5e10% MeOH in CH2Cl2) to yield the protected interme-
diate, 2,2,2-10-((Z)-28-octadec-9-enyloxy)-2,22,25-trioxo-6,9,12,15,18,30-hexaoxa-
3,21,26-triazaoctatetracont-39-enyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)trie-
thanoic acid tri-tert-butyl ester (199mg, 54%) as a light yellow oil. 1H NMR (600MHz;
CDCl3) d 0.87 (t, J ¼ 6.9 Hz, 6H), 1.26 (m, 44H), 1.44 (s, 27H), 1.55 (m, 4H), 2.0 (8H, m,
CH2CH]CHCH2), 2.52 (4H, m, OCCH2CH2CO), 3.20e3.65 (m, 35H), 5.34 (m, 4H), 6.42
(br s, 2H), 6.84 (br s, 1H), 6.98 (br s, 1H), notee signals masked under line broadening
2.0e3.2 ppm; 13C NMR (150 MHz; CDCl3) d 14.3, 22.8, 26.2, 27.3, 27.9e28.1 (signals
superimposed), 29.3e29.9 (signals superimposed), 30.2, 31.6, 31.9, 32.0, 32.7, 33.8,
39.2, 39.3, 40.9, 48.5 (br), 53.0 (br), 55.8 (br), 56.1, 56.8, 69.7, 70.0, 70.1, 70.2, 70.4, 71.5,
71.9, 81.8, 81.9, 82.3, 130.0, 130.5, 171.8, 172.4, 172.6, 173.2; m/z (ESþ) 1476 ([MNa e
tBu]þ, 100%). The tri-tert-butyl ester was then deprotected in 1:1 CH2Cl2:TFA (5 mL)
for 3 h at room temperature. The solvents were removed in vacuo and the product
dried under vacuo to give 17 as a colourless oil (quantitative yield). Rf 0.56 (10%MeOH
in CH2Cl2); nmax(CHCl3)/cm1 2926, 2856, 1736; 1H NMR (600 MHz; CD3OD) d 0.89 (t,
J ¼ 6.9 Hz, 6H), 1.30 (m, 44H), 1.56 (m, 4H), 2.02 (m, 8H), 2.48 (m, 4H), 3.18e3.64 (m,
35H), 5.33 (m, 4H), note e some signals masked under line broadening 2.9e3.6 ppm;
13C NMR (150 MHz; CDCl3) d 14.5, 23.8, 26.1, 27.3, 28.2, 28.5, 30.3e30.9 (signals
superimposed), 31.2, 32.2, 33.1, 33.7, 34.7, 38.9, 40.4, 41.6, 70.5 71.1e71.6 (signals
superimposed), 72.6, 78.6, 81.3, 130.8, 130.9, 162.9, 163.1, 167.5, 174.7, 174.9, 179.7;m/z
[HRMS ESþ] found, 1340.9716. C71H134N7O16 requires 1340.9887.
2.3. Liposome preparation and characterization
The Gd lipids Gd-DEG1SL, Gd-DEG3SL and Gd-DEG6SLwere prepared [14] from
15, 16 and 17, respectively, as follows. The free acid e macrocyclic lipids (15, 16, 17)
were each dissolved in 2 mL of distilled water, then 0.9 molar equivalents of GdCl3
were added. The solutions were heated at 90 C overnight, then freeze dried to
a powder and stored at 20 C. Successful chelation was conﬁrmed via Xylenol
Orange assay [44] and MALDI MS (Supplementary Data, Figs. S1eS3).
MALDI MS data for Gd-DEG1SL, 1274, 1275, 1276, 1277, 1278 g mol1
MALDI MS data for Gd-DEG3SL; 1361, 1362, 1363, 1364, 1365, 1366, 1367 gmol1
MALDI MS data for Gd-DEG6SL; 1493,1494, 1495, 1496,1497,1498, 1499 gmol1
All lipid components were dissolved in either CHCl3 or methanol to a concen-
tration of 1 mM. The lipids were mixed together in the appropriate molar ratios,
shown in Table 1 (incorporating Gd-lipids Gd-DEG1SL, Gd-DEG3SL and Gd-DEG6SL)
and Table 2 (incorporating the DOTA-lipids DEG1SL (15), DEG3SL (16) and DEG6SL
(17) for subsequent labelling of the liposomes with 64Cu or 111In) and the solvents
removed under reduced pressure to form a thin ﬁlm. This ﬁlm was further dried on
a high vacuum line for 4 h then hydrated with sterilized water, diluted to the
required concentration and stored at 4 C overnight. After this period the sample
was sonicated for 10 min and used immediately. For in vitro assays a bath sonicator
was used due to the small sample volume. For in vivo injections a probe sonicator
(Soniﬁer SLPe, Branson (USA)) was used. The liposomes were characterized by DLS
and zeta potential (Tables 1 and 2) according to manufacturers recommendations.
The samples were prepared by taking a 50 mL aliquot of the stock liposome solution,
which had a total lipid concentration of 3.33 mM, this was then diluted in H2O to
a ﬁnal volume of 1 mL. Both DLS and zeta potential measurements were performed
at 25 C, in triplicate, using a clear 1 mL zeta potential cuvette.
2.4. Phantom studies
A range of concentrations (serial dilutions 1e0.0625 mM) of Gd-DEG1SL, Gd-
DEG3SL and Gd-DEG6SL were used to calculate relaxivity of each contrast agent as
liposome formulations A e G. The relaxivities of these formulations were compared
to the relaxivity of Gd.DOTA (Dotarem). Phantoms were imaged by MR using a fast
spin-echo sequence with the following parameters to obtain images with increasing
T1-weighting; 10 TR’¼ 200e15,000ms, TE¼ 17ms, FOV¼ 40 40 cm, averages¼ 4:
matrix size ¼ 256  128: and a 1.0 mm thickness.
2.5. Radiolabeling with 111In
For Instant Thin Layer Chromatography (ITLC), the liposomes in water (20 mL)
were buffered with 0.1 M ammonium acetate buffer, pH 6 (20 mL). 111InCl3 (20 mL,
Table 1
Compositions, hydrodynamic sizes and zeta potentials of Gd-liposomes with oligoethylene glycol shielding (A, B, C), stealth lipid shielding (D) and without PEG shielding (E, F,
G).
Liposome DOPE Gd-lipid PEG-lipid DOTMA FL-DHPE DLS (PDI) Zeta
A 9% 30% Gd-DEG1SL 50% DODEG4 10% 1% 96.8 nm (0.2) (þ) 62 mV
B 9% 30% Gd-DEG3SL 50% DODEG4 10% 1% 92.9 nm (0.2) (þ) 56 mV
C 9% 30% Gd-DEG6SL 50% DODEG4 10% 1% 177 nm (0.2) (þ) 56 mV
D 2% 30% Gd-DEG3SL 7% DSPE-PEG2000 60% 1% 146 nm (0.3) (þ) 45 mV
E 9% 30% Gd-DEG1SL e 60% 1% 212.9 nm (0.3) (þ) 55 mV
F 9% 30% Gd-DEG3SL e 60% 1% 220.8 nm (0.4) (þ) 53 mV
G 9% 30% Gd-DEG6SL e 60% 1% 244.4 nm (0.3) (þ) 44 mV
N. Mitchell et al. / Biomaterials 34 (2013) 1179e1192118416 MBq) was added and the reaction incubated at 37 C for 90 min. A sample (10 mL)
of each reactionwas challenged with 50mM EDTA (2 mL) for 5 min to bind any free or
non-speciﬁcally bound 111In. Samples were then analysed by ITLC (Supplementary
Data, Table S2). Controls, using water in place of liposomes, were treated as per
the liposome samples.
For in vivo studies, the liposomes were prepared as above but with the following
changes; to the liposome solution (in sterilised water, 300 mL) were added 0.1 M
ammonium acetate buffer (pH 6.0, 300 mL) and 111InCl3 solution (200 mL). The sample
was incubated at room temperature overnight, after which the liposomes were
puriﬁed to remove free 111InCl3 by eluting through a PD10 size exclusion column (GE
Healthcare) prior to injection [45]. The radioactivity of the 111InCl3 solution was
around 45 MBq; in a typical example, from 41.5 MBq of 111InCl3 solution 22.12 MBq
of radiolabelled liposomes were recovered after puriﬁcation (radiochemical yield of
69.2% accounting for decay of 111In).
2.6. Radiolabelling with 64Cu
[64Cu]-CuCl2 was bufferedwith an equal volume of 1 M ammonium acetate, pH 6.
Typically, the liposomes in water (10 mL) were buffered with 0.1 M ammonium
acetate buffer, pH 6, (10 mL). Buffered 64Cu solution (10 mL, 3 MBq)was added and the
reaction incubated at 37 C for 30 min. A sample (10 mL) of each reaction was
challenged with 50 mM EDTA (2 mL) for 5 min to bind any free or non-speciﬁcally
bound 64Cu. Samples were then analysed by ITLC. Control, using water in place of
liposome, was treated as per the liposome samples.
Analysis of the radiolabelled liposomes was carried out by ITLC using ITLC-SA
(0.75  9 cm) with a 2 mL sample spotted at the origin, 1 cm from the bottom of
the strip, and run for 8 cm in 0.1 M citrate buffer, pH 5. ITLC strips were scanned on
a mini-TLC scanner and analysed with Laura software (LabLogic). For both 111In and
64Cu, analysis of the control reaction using 0.1 M ammonium acetate buffer alone
with no liposome gave 100% of the radioactivity at the solvent front using this ITLC
system (Supplementary Data, Tables S1 and S2).
2.7. In vitro studies
Human HeLa cervical cancer, OVCAR-3 ovarian cancer, and MDA-MB-231 breast
cancer cells were grown in T175 ﬂasks (Fisher Scientiﬁc, Loughborough, UK) in
Dulbecco’s modiﬁed Eagles medium (DMEM) (Invitrogen, Paisley, UK), supple-
mented with 10% heat inactivated fetal calf serum (GIBCO, Grand Island NY, USA) in
an humidiﬁed incubator at 37 C with 95% air and 5% CO2. Cells were grown to 100%
conﬂuence before being trypsinized, counted and then plated for in vitro
experiments.
HeLa, OVCAR-3 and MDA-MB-231 cells were plated at 5  105/well in 6 well
plates (formicroscope and FACS analysis) or 1106/ﬂask in a T25 ﬂask (forMRI) 24 h
prior to adding liposomes. The cells were washed in phosphate buffered saline (PBS)Table 2
Compositions of liposomes labeled with 64Cu (HeK) and 111In (LeP). Liposomes H, I, L,
formulation. Liposomes J, K, O and P were formulated using DEG6SL 17 then labelled w
lacking the DOTA-lipids. Samples L, N, O and P were used for in vivo biodistribution.
Liposome DOPE Cu/In-lipid PEG-lipid
H 10% 30% Cu-DEG3SL 50% DODEG4
I 10% 30% Cu-DEG3SL e
J 10% 30% Cu-DEG6SL 50% DODEG4
K 10% 30% Cu-DEG6SL e
L 9% 30% In-DEG3SL 50% DODEG4
M 10% 30% In-DEG3SL e
N 2% 30% In-DEG3SL 7% DSPE-PEG2000
O 9% 30% In-DEG6SL 50% DODEG4
P 2% 30% In-DEG6SL 7% DSPE-PEG2000
Control Q 40% e 50% DODEG4
Control R 50% e e(GIBCO, USA) and 2 mL of serum free or normal culture DMEM was added, followed
by 100 mL of either 1, 0.5, 0.025 mM of liposome or water as control. Cells were
incubated at 37 C for 2 h (normal culturemedia) or 4 h (serum freemedia). The cells
were washed using PBS and ﬂuorescence imaged using an inverted Zeiss Axiovert
S100 Microscope. After harvesting cells were counted using 4% Trypan Blue solution
(SigmaeAldrich, Dorset, UK) to assess the number of viable cells and then resus-
pended in 500 mL PBS for FACS scanning using a FACS Calibur (Becton Dickinson,
Franklin Lakes NJ, USA) to assess cell uptake (1  105 cells), or pelleted and resus-
pended in 1% agarose (Sigma, UK) (2 106 cells) and scanned byMRI using the same
set up and parameters as phantoms to assess T1 changes. (Supplementary Data
Fig. S5, Table S3).2.8. MRI data analysis (relaxivity and T1)
Images were analysed using ImageJ software (National Institutes of Health, USA
[46] with a region of interest (ROI) drawn to encompass as much of the sample as
possible. The mean signal intensities of the ROI’s at different TR values were
measured and used to calculate the MR relaxation time T1 using Graphpad Prism
(GraphPad, San Diego, USA). The longitudinal relaxivity r1 was determined from
a linear ﬁt of 1/T1 as a function of Gd3þ concentration (Table 3). Mean T1 values for
labelled cell pellets were derived and a two-tailed unpaired t-test assuming equal
variances performed to determine signiﬁcant difference, with a 5% level of statistical
signiﬁcance. The percentage change in T1 was also calculated for these samples.2.9. In vivo SPECT/CT acquisition and image analysis
Eight male NOD Scid gamma (NSG) mice (6e8 weeks old) (n ¼ 2 per liposome
L,N,O or P) were anaesthetized with an isoﬂurane/O2mix and a tail vein cannulated
for the delivery of approximately 10 MBq of 111In labelled liposomes in approxi-
mately 300e400 ml sterile saline. SPECT/CT scans were acquired for the whole body
with mice placed in the prone position immediately post injection and again at 3, 6
and 24 h using a NanoSPECT/CT scanner (Mediso, Hungary). CT images were
acquired using a 45 kVP X-ray source, 500 ms exposure time in 180 projections,
a pitch of 0.5 with an acquisition time of 11 min. CT was imaged prior to SPECT,
which was acquired using an exposure time of 1200 s, obtained over 24 projections
(50 s per projection), a 4-head scanner with 4  9 1 mm pinhole apertures in helical
scan mode with a total acquisition time of 36 min. CT images were reconstructed in
a 352  352 matrix using proprietary Bioscan InVivSCope (Bioscan, USA) software,
whereas SPECT images were reconstructed in a 256  256 matrix using HiSPECT
(ScivisGmbH, Bioscan). Images were fused and analysed using InVivoScope (Version
1.44, Bioscan). 3D ROI’s were created for heart, lung, liver, spleen, kidneys and
bladder at each time point using InviCRO 3D and the counts decay corrected and
compared to the total injected at the 40 min time point for each mouse to assessM and N were formulated using DEG3SL 16 then labelled with 64Cu or 111In post-
ith 64Cu or 111In post-formulation. Liposomes Q and R were formulated as controls
DOTMA FL-DHPE DLS (PDI) Zeta
10% e e e
60% e e e
10% e e e
60% e e e
10% 1% 73.9 nm (0.2) (þ) 54 mV
60% e e e
60% 1% 141.7 nm (0.2) (þ) 43 mV
10% 1% 70.1 nm (0.2) (þ) 50 mV
60% 1% 142.6 nm (0.2) (þ) 31 mV
10% e e e
50% e e e
Table 3
Comparison of relaxivities (r1) for PEGylated and non-PEGylated liposomes.
Liposome Gd-lipid PEG shielded r1/mM1 s1
A Gd-DEG1SL DODEG4 2.95
B Gd-DEG3SL DODEG4 2.29
C Gd-DEG6SL DODEG4 1.97
D Gd-DEG3SL DSPE-PEG2000 2.12
E Gd-DEG1SL e 3.05
F Gd-DEG3SL e 2.37
G Gd-DEG6SL e 1.78
N. Mitchell et al. / Biomaterials 34 (2013) 1179e1192 1185biodistribution and clearance. The bladder was removed from the 40 min and 3 h
images, allowing the images to be scaled so that theywere comparable to each other.
3. Results
3.1. Synthesis of DOTA chelating lipids
As we aimed to develop a multimodal liposomal formulation
which would also have an evenly coated n-EG shielding function-
ality, DOTA conjugates were prepared incorporating different
length short ethylene glycol spacers between the C18 unsaturated
lipophilic chains and the DOTA chelator. To enhance ready
assembly and further protrusion of the DOTA chelate on the exte-
rior of the nanoparticle a succinimide spacer was also incorporated.
Synthesis of the DOTA-conjugates was carried out as shown in
Scheme 1, incorporating an aminodiol skeleton with two unsatu-
rated oleyl chains via ether links, also present in the shielding
cationic lipid DODEG4 (Fig. 1) to be used in this study. Accordingly,
diamines 1, 2, and 3 [36,37] were readily mono-Boc protected to
give 4, 5 [34,35] and 6 [42] respectively. Addition of succinic
anhydride gave 7 [38], 8 and 9 in good yield. 3-Bis[(Z)-octadec-9-
enyloxy]propan-1-amine (10) was synthesized as previously re-
ported [39] and coupled to 7e9 using standard HBTU or DCC
chemistry, then directly deprotected to give 11, 12 and 13. These
were then conjugated to the macrocycle 4,7,10-tris-tert-butox-
ycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid 14,
synthesized using reported procedures [40] again using standard
HBTU reaction conditions. The tert-butyl ester products were
deprotected under acidic conditions to give 15, 16 and 17, the key
DOTA lipid chelates for incorporation of Gd3þ or other metal ions.
In order to investigate the use of these liposomes in MR imaging
applications, chelation of Gd3þ with 15, 16 and 17 was ﬁrst carried
out. The key lipid chelates were dissolved in distilled water and
stirred overnight at 90 C with GdCl3; 0.9 molar equivalents were
used to ensure that all of the Gd3þ was chelated. The solution was
lyophilized overnight and the free Gd3þ content quantitatively
analysed via the Xylenol Orange assay [44], conﬁrming negligible
free Gd3þ. MALDI MS analysis of the lipid salts gave the desired
masses, corresponding to lipids chelated to each of the seven stable
Gd isotopes (Supplementary Data, Figs. S1eS3).
3.2. Formulation of liposomes for use as MR contrast agents
To investigate the application of liposomes as multimodal
agents, co-formulation of the Gd3þ-lipids with multiple lipid
components was necessary. Introduction of a ﬂuorophore allows
tracking and quantiﬁcation of the nanoparticle via optical means,
therefore the commercially available ﬂuorophore-labelled lipid FL-
DHPE was employed. The fusogenic lipid DOPE was also used in the
formulations, along with the cationic lipids DOTMA and DODEG4.
In order to investigate the effects of the length of the linker of
the Gd-lipids on MR relaxivity, and PEG shielding of the liposome
on cellular uptake, a series of liposomes AeG were formulated
(Table 1). Liposomes AeC and EeGwere formulated with 9% DOPE,which is believed to promote liposome fusion with the endosomal
membrane and mediate endosomal escape of the payload once the
liposome has been internalized [47], and 1 mol% FL-DHPE was
added to all formulations. Gd-lipids Gd-DEG1SL (liposomes A and
E), Gd-DEG3SL (liposomes B, D and F) and Gd-DEG6SL (liposomes C
and G) were added at 30mol% to enable the liposomes to be imaged
using MR. In order to shield the liposomes from interactions with
other biomolecules and promote stability under physiological
conditions, liposomes A, B and C were formulated with 50 mol%
DODEG4, a non-cleavable tetraethylene glycol lipid that we have
developed previously [10]. At this high percentage it was reasoned
that the liposome should be coated with an even coverage of short
n-ethylene glycol units. For comparison, liposome D was formu-
lated with the stealth lipid DSPE-PEG2000 at 7 mol% (partially
replacing the DOPE in the other formulations) which has previously
been used at similar mol% to produce sterically shielded liposomes
[48]. Non-shielded liposomes E, F and G were formulated without
incorporating either DODEG4 or DSPE-PEG2000. For all formula-
tions, an appropriate amount of the cationic lipid DOTMA was also
added, to give liposomes with a total of 60% of positively charged
lipids incorporated.
Liposomes were formed using the thin-ﬁlm sonication method
[11], to give uniform liposomes of low polydispersity and hydro-
dynamic sizes ranging between 90 and 250 nm (Table 1). The non-
shielded liposomes E, F and Gwere signiﬁcantly larger, perhaps due
to aggregation. The zeta potential of liposomes AeG was also
measured (Table 1); despite the differences in PEG shielding, all
liposomes had similar, positive surface charges.
3.3. MR analysis of liposomal agents
Phantoms of serial dilutions from a 1 mM stock solution of Gd
labelled liposomes E, F and G, formulated without PEG shielding,
showed the relaxivity of the solutions to be 3.05, 2.37 and
1.78 mM1 s1 respectively (Table 3). These values are comparable
to the relaxivity of non-conjugated Gd.DOTA (Dotarem), which was
measured as 2.68 mM1 s1. This suggests that although the func-
tionalization of one arm of the DOTA macrocycle with the lipid
moiety does not adversely affect the relaxivity of the macrocyclic
compound. The fact that all the relaxivities are slightly different
suggests that the length of the n-EG linker does in fact have some
inﬂuence on the relaxivity.
Relaxivities of liposome formulations including the DODEG4
lipid were also measured, in order to investigate the effect of the
interaction between this lipid with a short (n ¼ 4) n-EG group
attached, and the various n-EG linker-lengths positioned between
the lipid head group and the DOTA chelator. Liposome formulations
A (containing Gd-DEG1SL) and B (containing Gd-DEG3SL) with
50 mol% DODEG4 show a very slight reduction in r1 compared to
their non-PEGylated counterparts E and F respectively (<5%). In
contrast, a slight increase in relaxivity is seen for C (containing Gd-
DEG6SL), compared to the non-pegylated liposomal formulation G.
This indicated that the short n-EG did not have a substantial further
effect on relaxivity when compared to the nonpegylated liposomes.
The relaxivity of liposome D, formulated with the lipid Gd-
DEG3SL (with a linker of intermediate length) and with the previ-
ously reported stealth lipid DSPE-PEG2000 was also measured. In
this case, the relaxivity of liposome D is comparable to the both the
other Gd-DEG3SL preparations if slightly reduced in comparison to
that of liposome B (with a shallow n-EG coating provided by
DODEG4) and liposome F (no EG coating). This suggests that the n-
EG linker on the DOTA-lipid has a greater inﬂuence on the relaxivity
than the n-EG or PEG shielding provided by the other lipids. None-
theless, both the n-EG and non-n-EG liposomes reduced T1 by
approx. 85e90% relative towater control and are therefore can all be
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Scheme 1. Synthesis of DOTA-lipids and Gd-DOTA lipids. Reagents and conditions: (i) (Boc)2O, CH2Cl2, 4 33%, 5 84%, 6 73%; (ii) NEt3, succinic anhydride, 7 55%, 8 90%, 9 58%; (iii) amine
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we are comparing the relaxivities relative to the gadolinium
concentration to assess the effect of the formulation on relaxivity.
However, the actual relaxivity for each liposome is much greater:
each liposome will incorporate multiple Gd-lipids, and thus the Gd
payload per nanoparticle [19] is increased.
3.4. Cellular uptake
Inclusion of the ﬂuorescein lipid allowed conﬁrmation and
quantitative analysis of cellular liposomal uptake using FACS(Supplementary Data, Fig. S4 and Table S3) and ﬂuorescence
microscopy (Fig. 2A, also Supplementary Data, Figs. S5 and S6) and
cell viability was also assessed by cell counting with Trypan Blue
(Supplementary Data, Fig. S7). All cell lines investigated (HeLa,
MDA-MB-231 and OVCAR-3) showed varying degrees of uptake for
both the n-EG-shielded liposomes A, B and C (Fig. 2) as well as the
non-shielded liposomes E, F and G (Supplementary Data, Fig. S5) by
ﬂuorescence microscopy. It was clear that the OVCAR-3 cells took
up the least of all three cell lines based on the MRI T1 relaxation,
with the MDA-MB-231 cells having the highest uptake (Fig. 2B).
However, the OVCAR-3 cells also appeared to be more sensitive to
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liposome incubation (Supplementary Data, Fig. S7). In contrast,
cells labelled with liposome D (containing PEG2000) were shown
to have less ﬂuorescence. This was the only liposome preparation to
present as a halo around the cell, indicative of being electrostati-
cally bound to the cell surface rather than internalised (Fig. 2A).
FACS (Supplementary Data, Table S3) conﬁrmed that cells incu-
bated with liposomes A-G were labelled (all liposomes label over
94% of cells) but that cells labelled with liposome D, although
exhibiting the same percentage labelling, had a reduced ﬂuores-
cence shift in the FACS plot (Supplementary Data, Fig. S4). FACS also
indicated that there were no differences in the labelling of cells
with E-F compared to A-C and also no differences in labelling of
samples labelled in serum free compared to normal culture media
(Supplementary Data, Table S3). However, ﬂuorescent images
suggested that the cells incubated with non-shielded liposomes
(Supplementary Data, Fig. S5) and the cells incubated with shielded
liposomes B and C in normal media (Supplementary Data, Fig. S6)
showed an increase in ﬂuorescence.
Out of liposomes AeC, liposome B (formulated with DEG3SL)
was the best tolerated at higher doses (Supplementary Data, Fig. S7:
1 mM and 0.5 mM) but showed the lowest uptake by ﬂuorescence.
Liposomes A and C had the highest uptake; however, highly ﬂuo-
rescent cells were seen to round at high doses losing adherence and
reducing cell viability at high concentration (1 mM and 0.5 mM) in
both cases (Supplementary Data, Fig. S7). n-EG-shielded liposomes
AeC showed less cell rounding compared to the non-shielded
equivalents EeF, suggesting DODEG4 inhibits excessive uptake. Of
the non-shielded liposomes, ﬂuorescence images of F (also
formulated with DEG3SL, as in B) had the highest ﬂuorescence, but
liposomes E and G labelled far fewer cells (Supplementary Data,
Fig. S5). This may be indicative of high uptake rounding and cell loss
prior to imaging, and the ﬂuorescence seen for E and G may
therefore be an underestimation. Uptake in cells in normal culture
media also resulted in more highly ﬂuorescent cells compared to
serum free media, indicating greater uptake, but again accompa-
nied by increased cell rounding (Supplementary Data, Fig. S6).
Finally, liposomeD, formulated including DSPE-PEG2000, led to the
least reduction in cell viability, probably because these liposomes
do not appear to be internalised.
MRI results (Fig. 2C) suggested that liposome B (the best toler-
ated by the cell lines) gave dose dependent T1 reduction with
maximal 27% decrease in T1 compared to unlabelled control cells.
Due to the increased uptake of liposomes A and C, leading to highly
ﬂuorescent cells with high concentrations of liposomes losing
adherence and reducing cell viability, liposomes A and C were not
used for MRI analysis. It could be presumed that the increase in
concentration of Gd-liposome within the cell would give a greater
effect on T1 for these liposome formations. However, due to
differences in their relaxativity and a reduction inwater interaction
due to internalizationwithin the cell any differences in T1 cannot be
predicted.
3.5. Liposome radiolabelling with Cu-64 and In-111
In order to extend the imaging repertoire of this delivery system
to include PET and SPECT, chelation of the appropriate radionu-
clides to give 64Cu or 111In-labelled liposomes was investigated. In
order to optimise the conditions for efﬁcient complexation, DOTA-
lipids DEG3SL (16) and DEG6SL (17) were initially labelled, unfor-
mulated, with 64Cu; labelling efﬁciencies of 96% (16) and 77% (17)
were obtained. (Supplementary Data, Table S1).
In the preceding in vitro MRI experiments, Gd-liposomes
formulated from Gd-DEG3SL or Gd-DEG6SL were observed to
have low and high uptake and internalization propertiesrespectively. Liposomes containing these DOTA-lipids were used
for post-formulation radiolabeling to give either 111In or 64Cu-
labelled liposomes. LiposomesHeM andO, composed of 30mol% of
the uncomplexed DOTA-lipidsDEG3SL orDEG6SL, were formulated
with and without DODEG4 (Table 2), ensuring, as in all previous
cases, that 60% of the lipids carry a positive charge, thus keeping the
net charge on the liposome consistent. For comparison, liposome N
was formulated with 7 mol% of DSPE-PEG2000 and 30 mol%
DEG3SL, and liposome P was formulated with 7 mol% of DSPE-
PEG2000 and 30 mol% DEG6SL, again adjusting the percentages
of DOTMA and DOPE to keep the net positive charge consistent.
Liposomes Q and R, with and without DODEG4, were formulated
without DOTA-lipids as controls.
Liposomes H, I, J, K, Q and R (at a concentration of 1 mM with
respect to the DOTA-lipid) were labelled with 3 MBq of 64Cu
(Table 2), and liposomes L,M,N, O and Pwere labelled with 16MBq
of 111In. After 1 h, EDTA was added to sequester any unbound ions.
The sample was analysed using TLC and plates were visualised with
a gamma detector. The labelling efﬁciency was high (76.0e81.7%)
for liposomes using 64Cu (Supplementary Data: Table S1). PEGyla-
tion of the particles had little effect on its complexing properties.
Control liposomes Q and R, without inclusion of the DOTA-lipids,
showed minimal (<6%) 64Cu uptake. Labelling efﬁciency with
111In (Supplementary Data: Table S2) was high for liposomes L
(78.4%) and M (88.0%) containing DEG3SL, with no signiﬁcant
difference between the DODEG4-shielded (L) and non-shielded (M)
formulations. The labelling efﬁciency was lower (36.6%) for lipo-
some O containing DEG6SL.
For in vivo injections, liposomes L, N, O and P were prepared
using probe sonication in order to obtain consistently small parti-
cles, with the size and zeta potential being measured prior to
labellingwithw45Mbq 111In and puriﬁcation using a PD10 column.
All liposome samples had low polydispersities, with the DODEG4
liposomes L and O being smaller and with a greater surface charge
than the DSPE-PEG2000 liposomes N and P.
3.6. In vivo SPECT imaging of In-111 labelled liposomes
DODEG4 liposomes L (DEG3SL) and O (DEG6SL) as well as
PEG2000 liposomes N (DEG3SL) and P (DEG6SL) were injected
intravenously to assess changes in distribution patterns over a 24 h
time course (Figs. 3 and 4). The bladder was removed from the
images (Fig. 3) at both the 40 min and 3 h time points so that the
thresholding of the uptake in the internal organs could be
compared. However, the data for the kidneys and bladder show
that almost half the radioactivity injected (w40% liposomes L & P
and w60% liposomes N & O) is being excreted at the 40 min time
point (Fig. 4). At 3 h therewas still some radioactivity in the bladder
for all liposome formulations but not at later time points although
the kidneys appear to retain some activity throughout (Figs. 3 and
4). All liposome preparations also showed rapid uptake within the
liver and spleen even at the 40 min time point. Liposomes L and P
had a much higher uptake at 40 min compared to N and O, which
may explain the slight reduction in their renal clearance at this time
point (Figs. 3 and 4). Liposome P also had the highest uptake within
the spleen, although both liposomes L and N presented fairly
similar uptakes. In the images, both of the PEG2000 liposomes
appear to show a characteristically high uptake in the spleen
compared to both DODEG4 liposomes. This may be indicative of
speciﬁc uptake into a select cell type within the spleen for these
liposomes (Figs. 3 and 4). After the initial uptake, at 40 min post-
injection further uptake in both the liver and spleen for most
liposome preparations appeared to be gradual over the 24 h as
indicated by the gradual decrease in radioactivity taken from the
heart (indicative of blood pool) which was similar in rate for all
Fig. 3. In vivo SPECT/CT distributions derived from an intravenous administration ofw10MBq labelled DODEG4 (left hand column) liposome preparations L and O, formulated with
DEG3SL and DEG6SL respectively, compared to the control DSPE-PEG2000 (right hand column) liposome preparations N and P formulated with DEG3SL and DEG6SL respectively,
over the course of 24 h (H e heart, L e liver, S e spleen, and K e kidney). The bladder has been removed from the 40 min and 3 h images, allowing the images to be scaled so they
were comparable to each other.
Fig. 4. The radioactivity derived from each organ at each time point for liposomal preparations DEG3SL/DODEG4 (L), DEG6SL/DODEG4 (O), DEG3SL/DSPE-PEG2000 (N), and
DEG6SL/DSPE-PEG2000 (P). This is expressed as a percentage of whole body activity at 40 min post-injection.
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similar half-lives and that it is therefore differences in uptake and
excretion that mostly characterises them. As liposome P (DEG6SL/
PEG2000) had the highest uptake in the liver and spleen followed
by L (DEG3SL/DODEG4) with liposomes N (DEG3SL/PEG2000) and
O (DEG6SL/DODEG4) having the lowest, there is no clear correla-
tion in the biodistribution that is characteristic to either the two
different PEG coatings or to the In-DOTA lipids.
4. Discussion
The aim of this study was to develop and optimise multifunc-
tional liposomes for a range of imaging modalities [26], and
simultaneously to act as effective passive delivery agents for
disease states such as tumour delivery via the EPR effect. In
previous work, liposomal formulations incorporating DSPE-
PEG2000 have been prepared for in vivo imaging or delivery
applications. The resulting large, bulky PEG coating is believed to
shield the liposomes, reducing their clearance via the RES, resulting
in a long blood half-life and signiﬁcant uptake within the intersti-
tial space of subcutaneous tumours over 24 h [2,3,5,6]. However,
liposomes formulated with the high percentages of DSPE-PEG2000
(7e10%) required for in vivo stability are poorly taken up into cells
in vitro [7], reducing the efﬁciency of delivery at the target tissue
and leading to uptake in unwanted tissues.
In the present study, we sought to combat these limitations of
PEG2000 shielding by formulating liposomes including a high
proportion (50%) of a cationic lipid, DODEG4 [10], bearing short n-
ethylene glycol units. We envisaged that this would lead to lipo-
somes with a uniform coverage of shallow PEG shielding, which
would still confer a long blood half-life without impairing cellular
uptake. To make the liposomes multifunctional for imaging we
have prepared lipids containing a chelator (DOTA) in the head
group, for the chelation of paramagnetic Gd3þ for MRI, and the
radionucleides 111In and 64Cu for SPECT and PET respectively, and
have co-formulated these with DODEG4, DOTMA, DOPE and ﬂuo-
rescent lipids. As the short oligoethylene glycol spacers on the
DODEG4 may interact with functional groups on the other lipid
components of the liposomes, three DOTA lipids, DEG1SL (15),
DEG3SL (16) and DEG6SL (17), were synthesized with different
length oligoethylene glycol spacer units between DOTA and the rest
of the lipid. For MRI imaging, the DOTA lipids were chelated with
Gd3þ to give Gd-DEG1SL, Gd-DEG3SL and Gd-DEG6SL respectively,
and liposomes were then formulated with the Gd-lpids (Table 1).
For PET/SPECT imaging, liposomes were ﬁrst formulated from the
DOTA lipids themselves and the radiotracers subsequently chelated
to the DOTA group post-formulation (Table 2). The qualities of the
resulting liposomes as imaging tracers, their uptake in a range of
tumour cell lines in vitro, and ﬁnally their in vivo distribution, were
evaluated and compared to similar liposome incorporating DSPE-
PEG2000 as a control.
Formulation with Gd-DEG1SL, Gd-DEG3SL and Gd-DEG6SL
resulted in liposomes with T1 relaxivities comparable to that of the
Gd.DOTA contrast agent Dotarem, commonly used in clinical
imaging applications. Liposomes were also evaluated with and
without the incorporation of the short PEG lipid, DODEG4, as well
as with PEG2000. Although there was a trend for the relaxivity to
go down slightly with PEG shielding in all liposomes except the Gd-
DEG6SL formulation, the PEG shielding afforded by DODEG4 did
not notably change the relaxivity of the particles. It has been
previously been thought that PEG incorporation increases the
relaxivities of liposomal MRI contrast agents, due to additional
macromolecular bulk structure, causing reduced tumbling rates
and hence increased Gd-metal water contact [16,27]. However,
other groups have also showed no difference in relaxivities at 1.5 Tbetween liposomes formulated with [49] and without [50] M-
PEG2000-PE.
In this study, the most inﬂuential factor in liposome relaxivity
was the length of the oligoethylene glycol spacer units between the
DOTA and the lipid head group. The lipid with the shortest oligo-
ethylene glycol spacer (Gd-DEG1SL) had an increased relaxivity
compared to Dotarem, whereas the longest (Gd-DEG6SL) had the
greatest reduction in relaxivity. Previous studies of liposomes
formulated from other Gd-lipids, such as Gd.DOTA.DSA, have also
been shown to have an enhanced relaxation compared to
commercially available Gd-chelates [16,19]. This effect appears to
depend on the Gd chelate being rigidly ﬁxed to the exterior surface
of the liposome, such that the nanocomplex rotates as a rigid body
thus reducing the rotational tumbling rate of these large nano-
complexes [51]. Other strategies to restrict the rotational motion of
the Gd-chelates in liposomal preparations, such as attaching the
DOTA directly to the alkyl chains [52] have also lead to enhanced
relaxivities. In our work, the DOTA chelate in Gd-DEG6SL has the
most motility away from the polar head group. This local motion
reduces the effective rotational tumbling rate and therefore lowers
relaxivity, as has been shown for other liposomal Gd-chelates [50].
In contrast, other studies of polymerised liposomes formulated
with Gd-chelates have shown that a longer linker between the Gd-
chelate and the lipid head group can actually lead to higher molar
relaxivities. This was attributed to greater separation between the
metal ion and the surface of the liposome, allowing improved
aqueous accessibility to the Gd3þ ion [53]. Gd3þ-DTPA-bisamides
have also been prepared possessing different alkyl chain lengths
where a double bond in the alkyl chain, compared to a saturated
chain, gave a more efﬁcient MRI contrast reagent due to greater
chain mobility and resulting water exchange [54]. However, in the
present study thewater exchange rate is not so critical for achieving
a high r1 at higher ﬁeld strengths [55]; the range between the three
Gd-lipids is minimal and Gd-DEG6SL is still very much classed as
a functional contrast agent, although there may be a greater
difference between liposomes formulated from the three Gd-lipids
at lower ﬁelds [49]. It must also be noted that the relaxivities for
each formulation was measured as a function of Gd concentration
to assess how our formulation affects relaxivity. However, as the
liposome contains numerous DOTA chelators (30%) the Gd payload
per liposome [16] is increased and thus the Gd relaxivity per lipo-
some is actually much higher.
Chelation of the radionucleides 111In and 64Cu for SPECT and PET
was carried out after formulation of the liposomes. The degree of
chelation of the radionucleides therefore gives information on how
the PEG coating affects the chelating efﬁciency of the DOTA. This
was carried out for formulations HeP. DEG3SL and DEG6SL lipo-
somes were evaluated with and without the short PEG lipid,
DODEG4, for 64Cu, and DEG3SL and DEG6SL liposomes were eval-
uated with both DODEG4 and DSPE-PEG2000 for 111In, as the
binding would be thought to be consistent for both metals. As our
initial studies with Gd3þ appeared to indicate that a shorter oli-
goethylene glycol spacer would lead to reduced availability of the
DOTA within the PEG layer that would hinder binding, DEG1SL
formulations were not evaluated. Liposome labelling for both 111In
and 64Cu was high (w80%) although slightly lower for DEG6SL
formulations than DEG3SL. This may again be due to the ﬂexibility
of the longer oligoethylene glycol spacer, causing folding of the
head group into the bilayer and reducing accessibility for binding.
These labelling efﬁciencies of 111In are slightly lower than those
obtained in a recent study by de Vries et al. [21] although these
were heated at 50 C rather than 37 C, which may aid in maximal
chelation. The DEG3SL/DSPE-PEG2000 liposome N and DEG6SL/
PEG2000 liposome P also showed similar binding efﬁciencies to the
DEG6SL/DODEG4 formulation O, when assessed by PD10
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does not inhibit radiolabeling of DOTA on the surface of liposomes.
Therefore, these liposomes are suitable nuclear agents for both
SPECT and PET scanning.
The in vitro uptake experiments showed that the three different
cancer cell types all labelled and internalised each of theGd chelated
liposome formulations A, B and C containing the oligoethylene
glycol spacer lipid DODEG4, although to differing degrees. Inter-
nalizationwas characterised by ﬂuorescence microscopy as circular
deposits within the cell, consistent with uptake within vesicles
within the cell. In general, both the MDA-MB-231 and HeLa cells
were fairly tolerant to liposome labelingwith theMDA-MB-231 cells
showing the highest uptake with the greatest reduction in T1,
whereas the OVCAR-3 cells appeared to be the most susceptible to
cell death but also had the lowest uptake corresponding to a low
reduction in T1. The Gd-DEG3SL liposome B was the best tolerated
but also showed the lowest uptake. Liposomes A and C were less
tolerated but showed a much higher uptake in cells by both ﬂuo-
rescence microscopy and FACS results. Therefore the degree of
uptake is affecting cell viability especially at the higher concentra-
tions in these formulations. We have conﬁrmed this by the dose
dependent effect that can be seen by using serial dilutions of Gd-
DEG3SL and cell viability. The equivalent non-shielded liposomes E,
F and G, formulated with DOTMA rather than DODEG4, showed
similar results by FACS to the results for A, B and C. Cellular uptake
was also not hindered by serum within the incubation media;
indeed, thepresence of serumactuallyenhanced the cellular uptake,
increasing ﬂuorescence and also reducing the rate of uptake,
resulting in similar cell viabilities as the shielded liposomes at 2 h
rather than 4 h incubation. This may result from the serum causing
the particles to stick to the cell surface, or in the presence of serum
uptake of aggregates is also seen. However, the DSPE-PEG2000
liposome, D, showed no cellular internalization, and although the
FACS results showed that the percentage of cells that were labelled
by liposome D was similar to the three DODEG4 liposome formu-
lations A, B and C, the degree of shift in ﬂuorescence was much
lower. In fact, when cells labelled with liposome D were visualised
byﬂuorescencemicroscopy, theﬂuorescence appeared as adull halo
around the cells, indicating that the liposomeswere only attached to
the outside of the cell and had not been internalised.
Formulations of bimodal cationic liposomes containing Gd-lipids
and ﬂuorescence markers, but without PEG shielding, have already
been shown to have good uptake properties within HeLa cells with
little effect on cell viability [16]. Such liposomes have also proven to
be effective for siRNAdelivery in vivo to OVCAR-3 cells [17]. However,
these papers did not compare the uptake of these non-shielded
liposomes with liposomes containing PEG2000 in their in vitro
experiments; rather, different formulations were utilised for the
in vivo experiments, making a comparison of the effectiveness of
liposomes coated with PEG2000 with non-shielded liposomes
impossible [16,17]. We hypothesise that the limited uptake of the
PEG2000-containing liposome D is most likely due to two factors.
Firstly, the long neutral PEG2000 lipid hides the charge of the lipo-
some, which affects cell uptake, as cells have been shown to prefer-
entially take up charged particles. Secondly, PEG2000 is hydrophilic
in character, which decreases the adsorption of serum proteins and
opsonins to the surface of the liposome bilayer, resulting in limited
interaction with cell walls, also reducing cellular uptake [1]. For this
reason, stealth liposomes formulated with PEG2000 lipids generally
require theuseof targeting ligands forenhancedcellularuptake [6,7].
Our results show that the use of the lipid DODEG4, with a short oli-
goethylene glycol spacer, for the preparation of shielded liposomes,
appears to limit this inhibiting effect on cellular uptake when
compared to liposomes formulated incorporating DSPE-PEG2000.
The differences in uptake for the different Gd-lipid formulations A,B andCmay relate to howprominent theneutrally chargedGd-DOTA
complex is on the surface. The relaxivitymeasurementsmay suggest
that the Gd-DOTA in the DEG1SL liposome, A, is buried within the
DODEG4shielding layer, as theoligoethyleneglycol spacers are about
the same length. Similarly, the 111In chelating experiments may
indicate that the DOTA chelates in theDEG6SL liposome C are folded
back into the oligoethylene glycol layer. However, the observed
differences in uptake are not correlated to the surface charge of these
particles, with liposomes B and C having similar positive zeta
potentials and liposome A having the most positive surface charge,
nor are they related to the size of the particles, with liposomes C and
D having signiﬁcantly greater hydrodynamic sizes than liposomes A
and B.
The pharmacokinetic properties of liposomes L, O, N and P, as
assessed by SPECT/CT, were also markedly different. Directly after
injection and at 3 h all liposome preparations showed uptake in the
bladder although free indium had been removed by PD10 puriﬁca-
tion. This may be partly due to the distribution of size within the
liposome formulations,with smaller sizes excretedvia thekidney.At
40minpost-injectionuptake in the liverandspleen couldbe seen for
all liposome preparations, which then gradually increased over the
24 h time course. The 111In-DEG6SL/DSPE-PEG2000 (P) showed the
highest liver and spleen uptake followed by 111In-DEG3SL/DODEG4
(L), whereas both the 111In-DEG3SL/DSPE-PEG2000 liposome (N)
and 111In-DEG6SL/DODEG4 liposome (O) were shown to have
a reduceduptake in the liver. However, liposomeNdid exhibit a high
uptake in the spleen, with a characteristic uptake pattern in images
that was consistent for both DSPE-PEG2000 liposomes. The gradual
increase in uptake over the 24 h indicates that a speciﬁc fraction
remains in the blood pool at the earlier time points. The reduction in
blood concentration is shown by the heart values over the 24 h and
indicates that all of the liposomes have fairly similar clearance rates.
The uptake and clearance differences between liposomes unfortu-
nately cannot currently be attributed to a speciﬁc component of the
liposomal formulation. There is no correlation between the degree
of uptake in liver and spleen that relates to either the changes in PEG
shielding between the DODEG4 and DSPE-PEG2000 formulations,
or to the differences in n-EG linker lengths between the In-DOTA
lipids in this study, although the images for liposomes formulated
with DSPE-PEG2000 do appear to show characteristic uptake in the
spleen.
These results are highly signiﬁcant, as they indicate for the ﬁrst
time that it may be possible to “tune” liposomes to change their
distribution in vivo, as we have shown fairly substantial changes by
just adjusting the depth and coverage of the PEG shielding and
matching this to the length of PEG spacers between the component
lipids and the functional groups attached to them. They also indi-
cate that, contrary to other literature in this area, shielding with
PEG2000 lipids is not always the predominant factor governing
distribution of liposomes in vivo, as liposomes N and P show very
different behaviours. Although the distributions differed between
formulation the blood clearance, as judged by activity in the heart,
was fairly similar. Therefore it is hard to predict differences which
might occur in the degree of uptake of these different liposomes in
tumour models by EPR. However, we have also shown that lipo-
somes formulated with DODEG4 shielding have a high cell uptake
in vitro, whereas liposomes formulated with DSPE-PEG2000 do not.
This would mean that drug delivery for these formulations would
be more efﬁcient and therefore deliver an effectively higher
payload to target cells, compared to DSPE-PEG2000 formulations,
when delivered passively. Further work will be required to deter-
mine the relationships between the depth and coverage of the n-EG
or PEG shielding, the length of n-EG spacer between lipid and
functional group, and the biodistribution and EPR uptake of these
formulations.
N. Mitchell et al. / Biomaterials 34 (2013) 1179e1192 1191Remarkably little previous work has been carried out to inves-
tigate the overall biodistribution of bimodal liposomes for imaging,
or the effects of changes in formulation on biodistribution.
Although the incorporation of radionuclides should allow for these
effects to be studied, to date no SPECT investigations of liposome
biodistribution have been published, with the exception of a key
study by Boerman et al [23] looking at the uptake of encapsulated
111In PEGylated liposomes, which interestingly also showed a high
uptake of liposomes within the spleen. Similarly, although the
inclusion of a paramagnetic label should makeMRI studies feasible,
only liver uptake has so far been quantiﬁed by analysing tissue T1 at
longitudinal time points for Gd-liposome formulations [16]. The
majority of reported biodistribution data has been acquired post
mortem by either ﬂuorescence [16e18], or Gd distribution [56], or
Geiger counting [23] measurements.5. Conclusions
We have prepared a series of chelating lipids with oligoethylene
glycol spacersofdiffering lengthsbetween theDOTAchelatorand the
lipid head group, and used these to formulate multifunctional lipo-
somes, bearing paramagnetic or radiotracer ions, and also bearing
ﬂuorophore lipids.We have shown that thesemultimodal liposomes
can be developed as functional MRI contrast agents similar to those
previously shown in the literature, as well as radionuclide tracers for
both PETand SPECT.When co-formulatedwith DODEG4, a lipidwith
a short n-EG spacer, to give shielded liposomes with a shallow but
even coverage of PEG, these non-targeted liposomes showed good
cellular internalization in a range of tumour cells compared to the
limitedcellularuptakeof liposomes formulatedwithDSPE-PEG2000.
Moreover, by matching the depth of PEG coverage afforded by
DODEG4 to the lengthof then-EGspacers of theDOTA lipids,wehave
shown that similar distributions and blood half-lives to DSPE-
PEG2000-stabilised liposomes can be achieved. We envisage that
liposomes functionalized in this manner should eventually be
capable of delivering high payloads of therapeutic drugs to tumour
cells, not just in vitro but also in vivo, without affecting the bio-
distribution characteristics shown by liposomes modiﬁed by long
chain PEG, but with an enhanced capability for cellular uptake and
internalization, bringing this technology one step closer to the clinic.Acknowledgements
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